8-KEarnings & ResultsExhibits & Filings

JOHNSON & JOHNSON 8-K Report, Financial Results (Jul 14, 2009)

Filed July 14, 2009For Securities:JNJ

Summary

Johnson & Johnson (JNJ) filed an 8-K on July 14, 2009, to report its second-quarter financial results for the period ended June 28, 2009. The filing primarily consists of a press release and supplementary financial data. While the 8-K itself doesn't contain in-depth analysis, it serves as the official notification of the company's performance during the quarter, which is crucial for investors tracking the company's progress against its financial targets and industry benchmarks. Investors should refer to the attached press release and supplementary data (Exhibit 99.15 and 99.2O) for specific details on sales, earnings, and any commentary provided by management regarding the quarter's performance. These documents will offer insights into the drivers of JNJ's results, including performance across its various business segments (Pharmaceuticals, Medical Devices and Diagnostics, and Consumer Health Care) and any forward-looking statements or guidance issued.

Key Highlights

  • 1Johnson & Johnson announced its second-quarter 2009 financial results on July 14, 2009.
  • 2The filing includes a press release (Exhibit 99.15) detailing the sales and earnings for the quarter ended June 28, 2009.
  • 3Unaudited comparative supplementary sales data and condensed consolidated statements of earnings are also provided (Exhibit 99.2O).
  • 4This 8-K serves as the official disclosure of the company's quarterly financial performance.
  • 5Investors are directed to the attached exhibits for specific financial details and management commentary.

Frequently Asked Questions

The main purpose of this 8-K filing is to publicly announce and provide the official financial results for Johnson & Johnson's second quarter ended June 28, 2009. It directs investors to the accompanying press release and financial statements for detailed information.

The specific sales and earnings numbers for the second quarter are detailed in the press release (Exhibit 99.15) and the Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings (Exhibit 99.2O) attached to this 8-K filing.

This 8-K filing primarily reports historical financial results. Any forward-looking statements or guidance from Johnson & Johnson management regarding future performance would be found within the attached press release (Exhibit 99.15).

Johnson & Johnson typically reports results across its three main business segments: Pharmaceuticals, Medical Devices and Diagnostics, and Consumer Health Care. Specific details for the second quarter would be available in the attached press release.